The European Union has approved MAVIRET (glecaprevir/pibrentasvir) for treating acute hepatitis C virus (HCV) infection in adults and children aged 3 and older. This is the only treatment in the EU approved for both acute and chronic HCV, enabling earlier intervention to reduce liver disease progression and transmission. The approval is based on a Phase 3 study showing 96.2% cure rates with an eight-week regimen and a favorable safety profile. AbbVie aims to support broader HCV elimination efforts with this new treatment option.
The European Commission has approved SKYRIZI (risankizumab) for treating moderate to severe plaque psoriasis in children and adolescents aged six and older. This approval includes a new 55 mg pre-filled syringe designed for weight-based dosing in pat...
AbbVie announced it will acquire Apogee Therapeutics in a $10.9 billion all-cash deal, gaining clinical-stage therapies for inflammatory and immunological diseases like atopic dermatitis and asthma. The acquisition includes Apogee's lead drug zumilok...
AbbVie announced it will acquire Apogee Therapeutics, a clinical-stage biotech company, for approximately $10.9 billion. This acquisition gives AbbVie control over Apogee's diverse pipeline of clinical-stage candidates focused on inflammatory and imm...
The global hyperpigmentation treatment market, valued at $1.52 billion in 2025, is projected to grow to $2.85 billion by 2035 at a CAGR of 6.5%. Growth is fueled by rising consumer awareness of skin aesthetics, increasing cases of pigmentation disord...
The Health Care Select Sector SPDR ETF (XLV) is down about 3% year-to-date despite a 14% gain over the past year. The fund's performance hinges on drug pricing policies and key product pricing, especially from Eli Lilly, which dominates XLV with its ...
